FRM
SUPN icon

Fox Run Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Fox Run Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,976
Closed -$640K – 1282
2026
Q1 		$640K Buy
+12,976
New +$661K 0.11% 330
2025
Q1 		– Sell
-35,900
Closed -$1.3M – 1217
2024
Q4 		$1.3M Buy
+35,900
New +$1.26M 0.24% 90
2019
Q2 		– Sell
-16,034
Closed -$562K – 617
2019
Q1 		$562K Buy
+16,034
New +$597K 0.32% 82
2018
Q2 		– Sell
-16,075
Closed -$736K – 902
2018
Q1 		$736K Sell
16,075
-5,900
-27% -$246K 0.18% 175
2017
Q4 		$876K Buy
+21,975
New +$868K 0.26% 91
2016
Q1 		– Sell
-15,400
Closed -$207K – 542
2015
Q4 		$207K Buy
+15,400
New +$238K 0.16% 305

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Fox Run Management's SUPN Position: Q2 2026 in Review

Fox Run Management sold out of Supernus Pharmaceuticals (SUPN) in Q2 2026, closing a stake of 12,976 shares — an estimated $640K sold.

Fox Run Management first reported a position in SUPN in Q4 2015 and held it in 6 quarters. The position peaked at $1.3M in Q4 2024. 334 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Fox Run Management reported no remaining Supernus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Fox Run Management sold 12,976 Supernus Pharmaceuticals shares in Q2 2026, an estimated $640K.
  • Fox Run Management first reported a position in Supernus Pharmaceuticals in Q4 2015 and held it in 6 quarters.
  • Fox Run Management's Supernus Pharmaceuticals position peaked at $1.3M in Q4 2024.
  • 334 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.